Costs of treating RA reducing in Norway due to national annual tender process.
In: PharmacoEconomics & Outcomes News, Jg. 882 (2021-07-10), Heft 1, S. 6-6
serialPeriodical
Zugriff:
Moreover, the average starting treatment cost decreased from NOK114 549 to NOK37 384 in patients initiating BTS treatment, and from NOK114 987 to NOK28 249 for patients naïve to BTSs. Additionally, for current BTS users, when the number of treated patients during follow-up doubled, the mean cost to treat one patient with BTSs reduced by approximately 50% (from NOK115 497 to NOK60 701 between 2010 and 2019). Over a ten-year period, annual total costs for BTSs and mean BTS costs per patient were calculated for all current, recently-initiated, and treatment-naïve BTSs users. [Extracted from the article]
Titel: |
Costs of treating RA reducing in Norway due to national annual tender process.
|
---|---|
Zeitschrift: | PharmacoEconomics & Outcomes News, Jg. 882 (2021-07-10), Heft 1, S. 6-6 |
Veröffentlichung: | 2021 |
Medientyp: | serialPeriodical |
ISSN: | 1173-5503 (print) |
DOI: | 10.1007/s40274-021-7840-7 |
Schlagwort: |
|
Sonstiges: |
|